Losartan is a prescription angiotensin receptor blocker, known by the brand name Cozaar, used to treat high blood pressure and to help protect the kidneys in some people with diabetes. Employees, caregivers, and HR teams sometimes ask whether a maintenance blood pressure medication could appear on a pre employment or random workplace drug screen. The short answer is that losartan is not one of the substances that standard workplace drug test panels are designed to detect, and the published literature does not document immunoassay cross reactivity for it. This article explains how screening panels actually work, what the medical review officer process does with a prescription, and what a lab confirmation test would show if a result is ever questioned.
What standard drug test panels actually screen for
A standard 5 panel, 10 panel, or 12 panel urine drug test is an immunoassay screen built to flag a defined list of drug classes, typically amphetamines, cocaine metabolites, opiates, phencyclidine, and THC metabolites on a basic panel, with additional classes such as benzodiazepines, barbiturates, methadone, and synthetic opioids added on extended panels. The immunoassay works by looking for antibody binding to a target drug or its metabolite. It is a fast, inexpensive screening step, not a definitive identification test. Losartan is an angiotensin II receptor antagonist. It does not belong to any of the drug classes that commercial immunoassay panels are built to detect, and it is structurally unrelated to amphetamines, opioids, benzodiazepines, or cannabinoids. The MedlinePlus consumer drug information page for losartan, maintained by the National Library of Medicine, describes it strictly as a blood pressure medication with no mention of controlled substance screening interactions.
Screening immunoassay versus lab confirmation
It helps to separate the two stages of workplace and clinical drug testing. The first stage is the immunoassay screen, run on a cup, dip card, or oral fluid device, or at a lab on an automated analyzer. It is a presumptive test, meaning a positive result is a signal to investigate further, not a final determination. The second stage, used whenever a screen comes back nonnegative, is confirmation by gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS or LC/MS/MS). Confirmation testing identifies the exact molecule present, down to a specific compound and concentration, rather than a class level antibody reaction. Because losartan does not trigger the antibody reactions that opiate, amphetamine, benzodiazepine, or THC immunoassays are designed around, there is no documented pathway for it to produce a nonnegative screen in the first place, and confirmation testing would not identify losartan as a controlled substance because it is not one. The DailyMed label for losartan potassium tablets, the government repository of official drug labeling run by the National Library of Medicine, lists its pharmacology, indications, and warnings and contains no reference to drug test interference.
Panel classes losartan is not part of
| Panel class commonly tested | Is losartan part of this class | Notes |
|---|---|---|
| Amphetamines / methamphetamine | No | Different chemical structure and mechanism of action |
| Opiates / opioids | No | Not an opioid receptor agonist |
| Cannabinoids (THC) | No | Not a cannabinoid |
| Benzodiazepines | No | Not a sedative or anxiolytic |
| Cocaine metabolites | No | No shared metabolic pathway documented |
| PCP | No | No structural similarity |
There is limited to no published evidence of losartan cross reacting with any immunoassay class used in federal or private workplace testing. If a nonnegative result ever occurs for an employee taking losartan, the more likely explanation is an unrelated substance, a different medication in their regimen, or, rarely, an assay specific quirk that confirmation testing will resolve. Employers and specimen collectors should never assume a reported medication explains a positive screen without the formal review process described below.
How a prescription is handled: the medical review officer process
Federally regulated testing programs, such as those covering transportation workers under Department of Transportation rules, require every nonnegative screen to be reviewed by a medical review officer (MRO), a licensed physician trained in substance abuse disorders and drug testing interpretation. The MRO contacts the employee directly, reviews any prescription medications and supporting documentation, and determines whether a legitimate medical explanation accounts for the result before it is ever reported to the employer as positive. This process is set out in 49 CFR Part 40, the federal regulation governing workplace drug and alcohol testing procedures, including MRO verification steps, interviews, and reporting standards. Because losartan is a legitimately prescribed, non controlled medication, an employee taking it as directed generally has nothing to disclose that would trigger special handling under a standard panel, but keeping a current prescription label or pharmacy record on hand is still good practice for any medication an employee takes, in case questions come up during a review.
What non DOT employers should ask, and not ask
Private employers running non regulated testing programs may design their own panels and review procedures, but should still follow a consistent, documented process. A reviewer or HR contact may ask an employee to list current prescription medications in a confidential medical review step, separate from the hiring decision itself. Employers should not ask for details about the underlying medical condition being treated, should not make employment decisions based on a legally prescribed, non impairing medication, and should keep any disclosed medication information confidential and limited to the personnel who need it for the review. The HHS Mandatory Guidelines for Federal Workplace Drug Testing Programs, published in the Federal Register and now codified at 42 CFR Part 84, describe the federal model for specimen collection, laboratory certification, and result review that many private programs voluntarily follow even when not legally required to.
What a positive result for someone on losartan would actually mean
If an employee taking only losartan for blood pressure receives a nonnegative screen on any panel, the result is very unlikely to be related to the losartan itself, based on the current absence of documented cross reactivity. The MRO review and, where applicable, GC/MS or LC/MS confirmation exist precisely to sort out exactly this kind of question before any adverse action is taken. Employees should always disclose current prescriptions during a confidential medical review when asked, and should keep documentation such as a pharmacy printout or prescription bottle available. Employers should never treat a disclosed, legitimately prescribed blood pressure medication as grounds for disqualification on its own, and should route every nonnegative result through the proper MRO or review process rather than making an independent judgment about what a medication does or does not explain.
Panel and program design for employers
American Screening Corporation supplies drug test cups, dip cards, and oral fluid devices used across standard 5, 10, and 12 panel configurations for pre employment, random, and reasonable suspicion testing programs. None of these standard configurations are designed to detect ARB blood pressure medications such as losartan, because they are built around drug classes with abuse potential, not prescription cardiovascular medications. Employers building or reviewing a testing program should confirm with their chosen laboratory exactly which analytes a given panel covers, since panel composition can vary by manufacturer and by state program requirements. Browse configurations at the drug test cup collection. For background on how another common blood pressure medication is handled on standard panels, see Does Lisinopril Show Up on a Drug Test?, and for a related diuretic often prescribed alongside losartan, see Does Hydrochlorothiazide Cause a False Positive Drug Test?.
Frequently asked questions
Does losartan show up as a positive on a standard drug test?
No. Losartan is not part of the drug classes that standard 5, 10, or 12 panel immunoassay screens are built to detect, and there is no documented cross reactivity for it in the published literature.
Could losartan cause a false positive for amphetamines or another class?
There is no credible published evidence of losartan cross reacting with amphetamine, opiate, benzodiazepine, THC, or other standard immunoassay classes. If a nonnegative result occurs while someone is taking losartan, it is more likely explained by another substance and should go through MRO review and confirmation testing.
Do I need to tell my employer I take losartan before a drug test?
Many employers include a confidential medical disclosure step as part of their testing process. Disclosing current prescriptions there, with documentation available, is good practice, though losartan generally has no bearing on standard panel results.
What is the difference between a screening test and a confirmation test?
The screening immunoassay is a fast presumptive test that flags possible drug classes. Any nonnegative screen should be confirmed with GC/MS or LC/MS, which identifies the specific substance present at a molecular level, before any result is treated as final.
Who reviews a nonnegative drug test result for someone on prescription medication?
A medical review officer (MRO), a licensed physician trained in drug testing interpretation, reviews nonnegative results, contacts the employee, and evaluates prescription documentation under the process described in 49 CFR Part 40 before a result is reported to an employer.
Can an employer refuse to hire someone because they take losartan?
Employers generally may not base an employment decision on a legally prescribed, non impairing blood pressure medication. Specific situations can vary, and employers should consult counsel about how disability and medication disclosure laws apply to their program.
This article is general information for employers and employees about how drug test panels and review procedures work. It is not legal or medical advice, and it is not a substitute for guidance from a medical review officer, physician, or employment counsel.
